• News
  • BioTech

Novo Nordisk shares tumble on drug review setback

Shares of Novo Nordisk are sinking in premarket trading after the Danish drugmaker said U.S. regulators want more data before they can finish their review of two long-acting insulin drugs to treat diabetes.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!